While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
Hyderabad-based peptide specialist strengthens complex generics credentials as Apotex prepares for U.S. commercialization of semaglutide injection
Discussions are likely to centre on how the country can move up the pharmaceutical value chain
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Subscribe To Our Newsletter & Stay Updated
